Aerocrine is delisted today

As previously announced, today is the last day of trading in the Aerocrine stock on Nasdaq Stockholm. Following completion of the recent public tender offer, Circassia Pharmaceuticals Plc ("Circassia") has initiated a mandatory redemption procedure to acquire all shares not already held by Circassia. Further information on the redemption procedure will be sent to remaining shareholders within short.

For more information, please contact:

Scott Myers, Chief Executive Officer, Aerocrine AB, Phone: +1 970 368 0336

About Aerocrine

Aerocrine AB is a medical products company focused on the improved management and care of patients with inflammatory airway diseases. As the pioneer and leader in technology to monitor and manage airway inflammation, Aerocrine markets NIOX MINO® and NIOX VERO®. Both products enable fast and reliable management of airway inflammation and may therefore play a critical role in more effective diagnosis, treatment and follow-up of patients with inflammatory airway diseases such as asthma. Aerocrine is based in Sweden with subsidiaries in the U.S., Germany, Switzerland and the U.K. Aerocrine shares were listed on the Nasdaq Stockholm Stock Exchange in 2007.